About Faex Health
Faex Health makes a smartphone app that uses AI to analyze images of stool. Users capture a stool image in the app. The app returns personalized digestive health insights, early warning indicators and wellness recommendations. The company builds it for consumers and for healthcare providers.
Faex Technologies Inc. does business as Faex Health and is based in Lafayette, Colorado. Landon Nattrass and Ryan Ninness founded it at the University of Colorado Boulder in May 2024. Nattrass is chief executive officer. Ninness is chief technology officer and the sole inventor of the core AI technology, with more than 25 years of experience in AI, machine learning and medical technology. The first enterprise customer is a health plan covering more than 50,000 employees, announced in May 2026.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 14, 2026 | Oct 29, 2026 | $2,500,000of $4.5M target | 2 | $1.2M | Equity, OptionsRule 506(b) | Form D ↗ |
| Sep 21, 2026 | Oct 7, 2026 | $38,888of $100K target | 2 | $19,444 | EquityRule 506(b) | Form D ↗ |
| May 6, 2026 | Aug 4, 2026 | $160,000fully sold | 4 | $40,000 | EquityRule 506(b) | Form D ↗ |
| Total, three offerings | $2,698,888 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed Faex Health
Faex Health sells an AI app that reads stool photos taken on a smartphone for gut health insights. It is aimed at consumers and healthcare providers. The company has launched a fundraising round to speed up work with health plans. It has also announced a clinical validation trial in Chile.
The problem it targets
The founders noticed that stool carries a lot of data about gut health. Millions of people flush it away daily. Chief executive officer Landon Nattrass says gut health is among the least monitored areas of healthcare, even though it is tied to serious disease. The founders' view is that a smartphone with AI can make this kind of monitoring accessible.
What the product does
The first prototypes were hardware that automated stool imaging. The team dropped that route, reasoning that hardware would slow adoption and put the technology out of reach for much of the world. The platform pre-screens for 16 gastrointestinal conditions. These include colorectal cancer, cholera and inflammatory bowel diseases. A Period Tracker feature, now live in the app, lets users log their menstrual cycle next to their gut health data. Separate research asks whether stool images could add a layer of outbreak surveillance. Nattrass says this is investigational research, and the platform is not meant to diagnose Ebola or replace laboratory testing.
Progress so far
In May 2026 the company announced its first enterprise customer, a health plan covering more than 50,000 employees. On May 18, 2026, it announced a trial in Chile with Hospital Dr. Sótero del Río. The trial tests whether phone-based stool analysis can help spot colonoscopy patients at higher risk of colorectal abnormalities. It will enroll patients who are already having standard colorectal screening. An earlier cholera pre-screening effort aimed to widen healthcare access in Africa. The company has now launched a fundraising round. Nattrass said the new money will go toward work with health plans, clinical validation and wider access to GI health tools in commercial and public health settings.
We wrote this summary from public statements by Faex Health and its investors. It is not investment advice.
Leadership Team
Executive officers and directors listed on Faex Health's Form D filed Oct 29, 2026.
